The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation

Cancer

Volumn 106, Issue 5, 2006, Pages 1017-1025

  Gu, Yan ^a   Swisher, Stephen G ^a   Ajani, Jaffer A ^a   Correa, Arlene M ^a   Hofstetter, Wayne L ^a   Liao, Zhongxing ^a   Komaki, Ritsuko R ^a   Rashid, Asif ^a   Hamilton, Stanley R ^a   Wu, Tsung Teh ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemoradiation; Esophagus; Lymph node; Metastasis; Prognosis

Indexed keywords

CISPLATIN; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33644525908     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21693     Document Type: Article

References (49)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049-2053.
2. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol. 2002;37:1359-1365.
3. Munoz N, Castellsague X. Epidemiology of oesophageal cancer. Eur J Gastroenterol Hepatol. 1994;6:649-655.
4. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450-464.
5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349:2241-2252.
6. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from 18 major cancers in 1985. Int J Cancer. 1993;55:891-903.
7. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-467.
8. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl Med. 1998;339:1979-1984.
9. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593-1598.
10. Urba SG, Orringer MB, Tunisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313.
11. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
12. Vogel SB, Mendenhall WM, Sombeck MD, et al. Downstaging of oesophageal cancer after preoperative radiation and chemotherapy. Ann Surg. 1995;221:685-695.
13. Naunheim KS, Petruska PJ, Roy TS, et al. Multimodality therapy for adenocarcinoma of the esophagus. Ann Thorac Surg. 1995;59:1085-1091.
14. Steward JR, Hoff SJ, Johnson DH, et al. Improved survival with neoadjuvant therapy and resection for adenocarcinoma of the oesophagus. Ann Surg. 1993;218:571-578.
15. Slater MS, Holland J, Faigel DO, Sheppard BC, Deveney CW. Does neoadjuvant chemoradiation downstage esophageal carcinoma? Am J Surg. 2001;181:440-444.
16. Terrosu G, Cedolini C, Bresadola V, et al. Preoperative chemoradiotherapy in cancer of the thoracic esophagus. Dis Esophagus. 2003;16:9-16.
17. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Cancer. 1994;73:2680-2686.
18. Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localised esophageal carcinoma. J Clin Oncol. 1996;14:156-163.
19. Heath El, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol. 2000;18:868-876.
20. Forrastiere AA, Orringer MB, Perez-Tamayo C, et al. Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. J Clin Oncol. 1993;11:1118-1123.
21. Wolfe WG, Vaughn AL, Seigler HF, et al. Survival of patients with carcinoma of the esophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg. 1993;105:749-756.
22. Ajani JA, Faust J, Yao J, et al. Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. Oncology. 2003;17:20-22.
23. Darnton SJ, Archer VR, Stocken DD, Mulholland PJ, Casson AG, Ferry DR. Preoperative mitomycin, ifosfamide, and cis-platin followed by esophagectomy in squamous cell carcinoma of the esophagus: pathologic complete response induced by chemotherapy leads to long-term survival. J Clin Oncol. 2003;21:4009-4015.
24. Geh JI, Crellin AM, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg. 2001;98:338-356.
25. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag, 2002.
26. Lerut T, DeKeyn P, Coosemsms W, et al. Surgical strategies in esophageal carcinoma with emphasis on radial lymphadenectomy. Ann Surg. 1992;216:583-590.
27. Nishimaki T, Suzuki T, Suzuki S, et al. Outcome of extended radical esophagectomy for thoracic esophageal cancer. J Am Coll Surg. 1998;186:306-312.
28. Eloubeidi MA, Desmond R. Prognostic factors for the survival of patient with esophageal carcinoma in the US. Cancer. 2002;95:1434-1443.
29. Tachibana M, Kinugasa S, Dhar DK, et al. Prognostic factors after extended esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Surg Oncol. 1999;72:88-93.
30. Kimura H, Konishi K, Arakawa H, et al. Number of lymph node metastases influences survival in patients with thoracic esophageal carcinoma: therapeutic value of radiation treatment for recurrence. Dis Esophagus. 1999;12:205-208.
31. Hsu CP, Chen CY, Hsia JY, Shai SE. Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus. Eur J Cardiothorac Surg. 2001;19:10-13.
32. Kawahara K, Maekawa T, Okabayashi K, et al. The number of lymph node metastases influences survival in esophageal cancer. J Surg Oncol. 1998;67:160-163.
33. Natsugoe S, Yoshinaka H, Shimada M, et al. Number of lymph node metastases determined by presurgical ultrasound and endoscopic ultrasound is related to prognosis in patients with esophageal carcinoma. Ann Surg. 2001;234:613-618.
34. Lerut T, Coosemans W, Decker G, et al. Extracapsular lymph node involvement is a negative prognostic factor in T3 adenocarcinoma of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg. 2003;126:1121-1128.
35. Chirieac LR, Swisher SG, Ajani JA, et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer. 2005;103:1347-1355.
36. Schroder W, Baldus SE, Monig SP, Beckurts TK, Dienes HP, Holscher AH. Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J Surg. 2002;26:584-587.
37. Imdahl A, Schoffel U, Ruf G, Hopf UT. Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients. Zentralbl Chir. 2004;129:350-355.
38. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364-372.
39. Lerut T, De Leyn P, Coosemans W, et al. Surgical strategies in esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg. 1992;216:583-590.
40. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester T. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234:520-531.
41. Collard JM, Otte JB, Fiasse R, et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg. 2001;234:25-32.
42. Altorki N, Skinner D. Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg. 2001;234:581-587.
43. Rice TW, Zuccaro G Jr., Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998;65:787-792.
44. Holscher AH, Bollschweiler E, Bumm R, Bartels H, Hofler H, Siewert JR. Prognostic factors of resected adenocarcinoma of the esophagus. Surgery. 1995;118:845-855.
45. Skinner DB. En bloc resection for neoplasms of the esophagus and cardia. J Thorac Cardiovasc Surg. 1983;85:59-71.
46. Nigro JJ. Node status in transmural esophageal adenocarcinoma and outcome after en bloc esophagectomy. J Thorac Cardiovasc Surg. 1999;117:960-968.
47. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg. 1981;194:585-591.
48. Komori T, Doki Y, Kabuto T, et al. Prognostic significance of the size of cancer nests in metastatic lymph nodes in human esophageal cancers. J Surg Oncol. 2003;82:19-27.
49. Doi N, Imada T, Aoyama N, Kameda Y, Koizumi H. Prognostic significance of the carcinoma area in the thickest part of the lymph node. Hepatogastroenterology. 2000;47:728-732.